Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen UPLIZNA (inebilizumab-cdon by Year
UPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — U.S. product sales ($M) ($M)
Amgen UPLIZNA (inebilizumab-cdon: $528M in FY2025, up 68.2% from a year earlier.
Where the FY2025 figure comes from
“|| UPLIZNA — U.S. (1) | 528 | 68 | % | 314 | * | 60”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | UPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 528 | +68.2% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 314 | +423.3% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 60 | – | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
Cite this data
StockData. (2026). Amgen UPLIZNA (inebilizumab-cdon ($M), annual FY2023–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-uplizna-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.